View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Flow Traders: Preview 4Q25 / Kinepolis: January reassures with US box office revenue up 14% YoY, France visitors up 15% YoY / Lotus Bakeries: Peer Mondelez 4Q25 results / MICC: Peer Mondelez 4Q25 results / RELX / Wolters Kluwer: Anthropic moves into Legal / Signify: Analyst lunch highlights / TomTom: 4Q25 results, bridging a gap / UCB: Evenity sales exceeded US$2.1bn in FY25 as per Amgen

Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri
Guy Sips ... (+5)
  • Guy Sips
  • Jacob Mekhael
  • Mathijs Geerts Danau
  • Wim Hoste
  • Wim Lewi
Martin Marandon-Carlhian ... (+2)
  • Martin Marandon-Carlhian
  • Stephane Houri
Jacob Mekhael
  • Jacob Mekhael

UCB Presents supportive three-year Bimzelx data in HS at EHSF

UCB announced that three-year data from the BE HEARD trials for Bimzelx in moderate to severe HS will be presented at the Conference of the European Hidradenitis Suppurativa Foundation EHSF, being held 4–6 February in Malta. The data show high rates of total HS resolution at 3 years, high rates of improvement from moderate or severe HS to mild disease, as well as strong draining tunnel resolution. This continues to highlight Bimzelx' benefit in this patient group, which we believe will further d...

Guy Sips
  • Guy Sips

Melexis FIRST LOOK: Remaining in an uneven recovery

Melexis saw in 4Q25 still a challenging and unstable environment as the automotive industry demand continues to be cautious and choppy between quarters. They indicated they remain in an uneven recovery. Melexis highlighted that -looking at FY26- 1Q is traditionally impacted by annual customer pricing agreements and seasonal factors such as Chinese New Year and sales patterns outside of automotive. In addition, this year demand is affected by recent changes in EV automotive regulations and purcha...

Mathijs Geerts Danau
  • Mathijs Geerts Danau

Onward Medical Announces enrolment of first participant in Empower BP ...

Onward announces enrolment of the first participant in the Empower BP trial. The trial evaluates the ARC-IM system to address blood pressure instability in SCI patients. We note that Onward plans an interim analysis of the efficacy results in 2H26, which could accelerate timelines if fewer total patients are required. Short-term, we look forward to the FY25 results to gain a view on the ARC-EX commercial launch (9M25: 70 devices sold). We reiterate our € 8.9 TP and BUY rating.

Wim Hoste
  • Wim Hoste

Akzo Nobel Uninspiring 4Q & FY26 outlook, while Axalta merger can beco...

Akzo's 4Q25 results were roughly in line with previous quarters, with weak volumes and negative FX leading to a slight decline in adjusted EBITDA, despite sizeable efficiency improvement initiatives. 2026 is expected to bring more of the same, with Akzo forecasting flat volumes and an FY26 adjusted EBITDA that is guided to be up at least 2% (or at least 7% excluding negative FX and scope effects). With current efficiency improvement initiatives expected to have mostly run their course in 2027, t...

Wim Lewi
  • Wim Lewi

Elia Group German government agrees on 25.1% Tennet stake

Yesterday, the German government (via KfW) secured a 25.1% "blocking minority" in TenneT's German operations. The €3.3bn deal ends years of negotiations between Germany and the Netherlands. The deal is struck at the same equity value following the capital contribution (46%) from ABP, GIC and Norges Bank in 09/25 at a total equity value of 13.3bn. TenneT NL will hold the remaining 28.9%. We understand from the Handelsblatt that KfW will invest an additional €1.7bn before 2035. TenneT GE will no...

 PRESS RELEASE

ONWARD Medical Announces First Participant Enrolled in Global Pivotal ...

ONWARD Medical Announces First Participant Enrolled in Global Pivotal Study Evaluating ARC-IM System to Address Blood Pressure Instability After Spinal Cord Injury Empower BP is a landmark global pivotal study evaluating the safety and effectiveness of the implantable ARC-IM® System to address blood pressure instability after spinal cord injury (SCI)Blood pressure instability is a key unmet need after SCI, with a significant impact on cardiovascular health and quality of lifeThe first participant was enrolled at Craig Hospital in Denver, Colorado, USA EINDHOVEN, the Netherlands, Feb. 04, ...

 PRESS RELEASE

Melexis Q4 and FY 2025 results

Melexis Q4 and FY 2025 results Regulated information Intermediate declaration by the Board of Directors Ieper, Belgium - February 4th, 2026, 07.00 hrs CET Dear, Please find herewith the link to our most recent press release: Attachment

 PRESS RELEASE

Melexis Q4 en FY 2025 resultaten

Melexis Q4 en FY 2025 resultaten Gereglementeerde informatie  Tussentijdse verklaring, opgesteld door de Raad van BestuurIeper, België - 4 februari 2026, 07.00 uur CET Geachte, hieronder vindt u de link naar ons meest recente persbericht: Bijlage

 PRESS RELEASE

Melexis Q4 et FY 2025 résultats

Melexis Q4 et FY 2025 résultats nformation réglementée Déclaration intermédiaire par le Conseil d'administrationYpres, Belgique - le 4 février 2026, 07.00 H. CET Veuillez trouver ici le lien vers notre dernier communiqué de presse: Pièce jointe

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aalberts: Preview: Another quarter in no man's land? / Ahold Delhaize: Confirms the acquisition of Delfood / AGEAS: China – state to inject capital into insurers / AkzoNobel: Tepid 4Q25 results and FY26 outlook / D'Ieteren: Belgian car registrations down 19%, 65% of 2019 level, VW down only 5% / Xior Student Housing: Sound organic trends continue, two-year guidance revealed

Guy Sips ... (+4)
  • Guy Sips
  • Jacob Mekhael
  • Wim Hoste
  • Wim Lewi
Stefano Toffano
  • Stefano Toffano
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch